Skip to main content
. 2014 Dec 23;9(12):e115600. doi: 10.1371/journal.pone.0115600

Figure 4. CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line.

Figure 4

Isogenic oncogenic progression in HBEC 3KT. Immortalized HBECs with (A) lenti-KRas V12, (B) lenti-KRas V12 and shp53 knockdown, and (C) lenti-KRas V12, shp53, and myc overexpression. Only lenti-KRas V12 cells are still moderately protected by CDDO-Me, but further oncogenic changes eliminate the radioprotective effects of CDDO-Me. (D) HBEC 30KT are protected by CDDO-Me. (E) HCC 4017, a NSCLC isolated from the same patient from which HBEC 30KT was derived, are unprotected by CDDO-Me. (F) Increasing concentrations to 50 nM still enhances clonogenic survival of HBEC 30KT, but actually seems to decrease survival in HCC 4017 after 3 Gy radiation. Mean ± SEM of three experiments seeded in triplicate, **p<0.01, t-test (compared to DMSO at 3 Gy).